Cargando…

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

Selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist fasiglifam (TAK-875), an antidiabetic drug under phase 3 development, potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic β cells. Although fasiglifam significantly improved glycemic contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yabuki, Chiori, Komatsu, Hidetoshi, Tsujihata, Yoshiyuki, Maeda, Risa, Ito, Ryo, Matsuda-Nagasumi, Kae, Sakuma, Kensuke, Miyawaki, Kazumasa, Kikuchi, Naoya, Takeuchi, Koji, Habata, Yugo, Mori, Masaaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/ https://www.ncbi.nlm.nih.gov/pubmed/24130766 http://dx.doi.org/10.1371/journal.pone.0076280

Ejemplares similares

Fasiglifam (TAK‐875) has dual potentiating mechanisms via Gαq‐GPR40/FFAR1 signaling branches on glucose‐dependent insulin secretion
por: Sakuma, Kensuke, et al.
Publicado: (2016)

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury
por: Wolenski, Francis S., et al.
Publicado: (2017)

Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1
por: Lückmann, Michael, et al.
Publicado: (2019)

Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 (GPR40) Agonist, May Induce Hepatotoxicity through Reactive Oxygen Species Generation in a GPR40-Dependent Manner
por: Kim, MinJeong, et al.
Publicado: (2018)

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial
por: Kaku, K, et al.
Publicado: (2015)

Optimization of First-in-Class Dual-Acting FFAR1/FFAR4 Allosteric Modulators with Novel Mode of Action
por: Lückmann, Michael, et al.
Publicado: (2022)

The allosterically modulated FFAR2 is transactivated by signals generated by other neutrophil GPCRs
por: Lind, Simon, et al.
Publicado: (2023)

A high molar activity (18)F-labeled TAK-875 derivative for PET imaging of pancreatic β-cells
por: Dornan, Mark H., et al.
Publicado: (2018)

Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus
por: Naik, H, et al.
Publicado: (2013)

Expression of FFAR3 and FFAR4 Is Increased in Gastroesophageal Reflux Disease
por: Fabisiak, Adam, et al.
Publicado: (2020)

TAK-875 Mitigates β-Cell Lipotoxicity-Induced Metaflammation Damage through Inhibiting the TLR4-NF-κB Pathway
por: Chen, Xide, et al.
Publicado: (2019)

Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury
por: Longo, Diane M, et al.
Publicado: (2019)

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
por: Marcinak, John, et al.
Publicado: (2018)

FFAR2-FFAR3 receptor heteromerization modulates short-chain fatty acid sensing
por: Ang, Zhiwei, et al.
Publicado: (2018)

Molecular characterization of free fatty acid receptors FFAR2 and FFAR3 in the domestic cat
por: Yamamoto, Ichiro, et al.
Publicado: (2020)

Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes
por: Kaku, Kohei, et al.
Publicado: (2013)

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function
por: Mayer, Michael, et al.
Publicado: (2014)

FFAR2 antagonizes TLR2- and TLR3-induced lung cancer progression via the inhibition of AMPK-TAK1 signaling axis for the activation of NF-κB
por: Kim, Mi-Jeong, et al.
Publicado: (2023)

Omega-3 Fatty Acids and FFAR4
por: Oh, Da Young, et al.
Publicado: (2014)

Mechanistic Studies on the Stereoselectivity of FFAR1 Modulators
por: Teng, Dan, et al.
Publicado: (2022)

Correction to Lancet Psychiatry 2020; 7: 875–82
Publicado: (2020)

Temporal and Spatial Transcriptional Fingerprints by Antipsychotic or Propsychotic Drugs in Mouse Brain
por: Sakuma, Kensuke, et al.
Publicado: (2015)

Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor
por: Cong, Zhaotong, et al.
Publicado: (2021)

Molecular mechanism of fatty acid activation of FFAR1
por: Kumari, Punita, et al.
Publicado: (2023)

Effect of short chain fatty acids on the expression of free fatty acid receptor 2 (Ffar2), Ffar3 and early-stage adipogenesis
por: Frost, G, et al.
Publicado: (2014)

875 Prospective Monitoring of Indwelling Urinary Catheters in Hospitalized Patients
por: Yoon, Bona, et al.
Publicado: (2014)

Lipid-Sensing Receptor FFAR4 Modulates Pulmonary Epithelial Homeostasis following Immunogenic Exposures Independently of the FFAR4 Ligand Docosahexaenoic Acid (DHA)
por: Sveiven, Stefanie N., et al.
Publicado: (2023)

Variants in the FFAR1 Gene Are Associated with Beta Cell Function
por: Kalis, Martins, et al.
Publicado: (2007)

Ffar2 expression regulates leukaemic cell growth in vivo
por: Bindels, Laure B, et al.
Publicado: (2017)

Human and mouse monocytes display distinct signalling and cytokine profiles upon stimulation with FFAR2/FFAR3 short-chain fatty acid receptor agonists
por: Ang, Zhiwei, et al.
Publicado: (2016)

Potential Utility of Biased GPCR Signaling for Treatment of Psychiatric Disorders
por: Komatsu, Hidetoshi, et al.
Publicado: (2019)

Does FFAR4 Agonism have Therapeutic Potential in Cardiometabolic Disease?
por: Lay, Abigail C
Publicado: (2021)

Upregulated expression of FFAR2 and SOC3 genes is associated with gout
por: Orji, Oliver C, et al.
Publicado: (2022)

875. Sex Differences in Academic Achievement and Faculty Rank in Academic Infectious Diseases
por: Manne-Goehler, Jennifer, et al.
Publicado: (2018)

Dysfunctional GPR40/FFAR1 signaling exacerbates pain behavior in mice
por: Nakamoto, Kazuo, et al.
Publicado: (2017)

Free Fatty Acid Receptors (FFARs) in Adipose: Physiological Role and Therapeutic Outlook
por: Al Mahri, Saeed, et al.
Publicado: (2022)

FFAR from the Gut Microbiome Crowd: SCFA Receptors in T1D Pathology
por: Priyadarshini, Medha, et al.
Publicado: (2021)

Anti-Atherosclerotic Potential of Free Fatty Acid Receptor 4 (FFAR4)
por: Kiepura, Anna, et al.
Publicado: (2021)

Butyrate dictates ferroptosis sensitivity through FFAR2-mTOR signaling
por: Wang, GuoYan, et al.
Publicado: (2023)

Hepatoprotective Effect of a New FFAR1 Agonist—N-Alkylated Isobornylamine
por: Pon`kina, Darya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k5e5hkt4samulup2pr2ebsbj3g